Our findings reveal a novel oncogenic functional interplay between MEK1/2, ABL1 and BCR signaling kinases, which if pharmacologically disabled by antagonizing MEK1/2 actions renders leukemia cells more responsive to the antitumor agent ATO with consequent implications for the treatment TKI-resistant Ph+ leukemias. The gene discussed is MAP2K1; the disease is leukemia.